
Top 3 SPAC Targets – Pharma Manufacturers
As discussed in the last iteration of this column focused on late-stage biotech firms, SPACs have increasingly turned to the drug development sector as a safe space on the board while various types of volatility have cropped up in the fourth quarter of 2026. More
Nicholas Alan Clayton·Nov 12





